Yaz 0.02 mg/3 mg film-coated tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Ethinylestradiol; Drospirenone

Available from:

Bayer Limited

ATC code:

G03AA; G03AA12

INN (International Name):

Ethinylestradiol; Drospirenone

Dosage:

0.02 mg/3 milligram(s)

Pharmaceutical form:

Film-coated tablet

Prescription type:

Product subject to prescription which may be renewed (B)

Therapeutic area:

Progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

Authorization status:

Marketed

Authorization date:

2008-10-17

Patient Information leaflet

Page
1
of
21
BP23002_REC20788+REC30040
PACKAGE LEAFLET: INFORMATION FOR THE USER
Yaz 0.02 mg/3 mg film-coated tablets
ethinylestradiol/drospirenone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
IMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES
(CHCS):
-
They are one of the most reliable reversible methods of contraception
if used correctly
-
They slightly increase the risk of having a blood clot in the veins
and arteries, especially
in the first year or when restarting a combined hormonal contraceptive
following a
break of 4 or more weeks
-
Please be alert and see your doctor if you think you may have symptoms
of a blood clot
(see section 2 “Blood clots”).
WHAT IS IN THIS LEAFLET
1.
What Yaz is and what it is used for ...............................................................................
2
2.
What you need to know before you take Yaz ................................................................ 3
When you should not use Yaz .......................................................................................
3
Warnings and precautions .............................................................................................
4
Blood clots ....................................................................................................................
5
Yaz and cancer ............................................................................................................
10
Psychiatric disorders ...................................................................................................
11
Bleeding between periods .................

Summary of Product characteristics

Health Products Regulatory Authority
26 June 2023
CRN00DFPG
Page 1 of 17
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Yaz 0.02 mg/3 mg film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
24 light pink film-coated tablets:
Each film-coated tablet contains 0.020 mg ethinylestradiol (as betadex
clathrate) and 3 mg drospirenone.
Excipient with known effect: lactose 46 mg (as lactose monohydrate
48.18 mg)
4 white placebo (inactive) film-coated tablets:
The tablet does not contain active substances.
Excipient with known effect: lactose 22 mg (as lactose monohydrate
23.21 mg)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet
The active tablets are light pink, round with convex faces, one side
marked with the letters "DS" in a regular hexagon.
The placebo tablets are white, round with convex faces, one side
marked with the letters "DP" in a regular hexagon.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Oral contraception.
The decision to prescribe YAZ should take into consideration the
individual woman’s current risk factors, particularly those for
venous thromboembolism (VTE), and how the risk of VTE with YAZ
compares with other Combined Hormonal Contraceptives
(CHCs) (see sections 4.3 and 4.4).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_METHOD OF ADMINISTRATION: _oral use
_POSOLOGY_
HOW TO TAKE YAZ
The tablets must be taken every day at about the same time, if
necessary with a little liquid, in the order shown on the blister
pack. Tablet taking is continuous. One tablet is to be taken daily for
28 consecutive days. Each subsequent pack is started the
day after the last tablet of the previous pack. Withdrawal bleeding
usually starts on day 2-3 after starting the placebo tablets
(last row) and may not have finished before the next pack is started.
HOW TO START YAZ
● No preceding hormonal contraceptive use (in the past month)
Tablet-taking has to start on day 1 of the woman’s natural cycle
(i.e. the first day of her menstrual bleeding).
�